MX354653B - Métodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteína 1 similar a transducina b (tbl1), que incluyen la neoplasia mieloproliferativa y la leucemia mieloide crónica. - Google Patents

Métodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteína 1 similar a transducina b (tbl1), que incluyen la neoplasia mieloproliferativa y la leucemia mieloide crónica.

Info

Publication number
MX354653B
MX354653B MX2014005498A MX2014005498A MX354653B MX 354653 B MX354653 B MX 354653B MX 2014005498 A MX2014005498 A MX 2014005498A MX 2014005498 A MX2014005498 A MX 2014005498A MX 354653 B MX354653 B MX 354653B
Authority
MX
Mexico
Prior art keywords
treatment
myeloid leukemia
protein
transducin
beta
Prior art date
Application number
MX2014005498A
Other languages
English (en)
Other versions
MX2014005498A (es
Inventor
N Bhalla Kapil
Horrigan Stephen
Original Assignee
Beta Cat Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Cat Pharmaceuticals Llc filed Critical Beta Cat Pharmaceuticals Llc
Publication of MX2014005498A publication Critical patent/MX2014005498A/es
Publication of MX354653B publication Critical patent/MX354653B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Abstract

La presente invención describe la utilización del compuesto de dioxima de antraceno-9,10-diona: dioxima de 2-((3R,5S)-3,5-dimetil piperdin-iIsulfonilo)-7-((3S, 5R)-3,5-dimetilpiperidin- 1- ilsulfonil)antraceno-9,10-diona para el tratamiento del cáncer, que incluye neoplasia mieloproliferativa, leucemia mieloide crónica y leucemia mieloide aguda. Tal compuesto de dioxima de antraceno-9,10-diona interrumpe la ruta de Wnt/beta-catenina e inhibe la actividad desregularizada de esta ruta para el tratamiento, la diagnosis y la prevención de los trastornos relacionados con la ruta de beta-catenina, así como interfiere en la interacción de la proteína 1 similar a la transducina beta (TBL1, por sus siglas en inglés) con la molecula coactivadora. beta-canina.
MX2014005498A 2011-11-06 2012-11-06 Métodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteína 1 similar a transducina b (tbl1), que incluyen la neoplasia mieloproliferativa y la leucemia mieloide crónica. MX354653B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161556245P 2011-11-06 2011-11-06
PCT/US2012/063746 WO2013067547A1 (en) 2011-11-06 2012-11-06 METHODS FOR TREATMENT OF DISEASES AND DISORDERS RELATED TO TRANSDUCIN β-LIKE PROTEIN 1 (TBL 1) ACTIVITY, INCLUDING MYELOPROLIFERATIVE NEOPLASIA AND CHRONIC MYELOID LEUKEMIA

Publications (2)

Publication Number Publication Date
MX2014005498A MX2014005498A (es) 2016-05-05
MX354653B true MX354653B (es) 2018-03-07

Family

ID=48192926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005498A MX354653B (es) 2011-11-06 2012-11-06 Métodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteína 1 similar a transducina b (tbl1), que incluyen la neoplasia mieloproliferativa y la leucemia mieloide crónica.

Country Status (16)

Country Link
US (1) US9238030B2 (es)
EP (1) EP2773607B1 (es)
JP (1) JP6063472B2 (es)
KR (1) KR102336767B1 (es)
CN (1) CN103917514B (es)
AU (1) AU2012332111B2 (es)
BR (1) BR112014010584A2 (es)
CA (1) CA2853491C (es)
EA (1) EA027770B1 (es)
ES (1) ES2624427T3 (es)
HK (1) HK1198440A1 (es)
IL (1) IL232452A (es)
MX (1) MX354653B (es)
SG (1) SG11201402056XA (es)
WO (1) WO2013067547A1 (es)
ZA (1) ZA201403003B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963475B2 (en) * 2015-07-28 2018-05-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
US9725473B2 (en) * 2015-07-28 2017-08-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
WO2018223023A1 (en) 2017-06-02 2018-12-06 Beta Cat Pharmaceuticals, Inc. Methods for treatment of fibrotic diseases
WO2019099836A1 (en) * 2017-11-16 2019-05-23 Northwestern University Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases
WO2019229001A1 (en) * 2018-05-30 2019-12-05 Otto-Von-Guericke-Universität Magdeburg Compounds for the treatment of jak2-v617f-associated cmn

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871493C (en) * 2007-05-10 2017-03-28 Dogwood Pharmaceuticals, Inc. Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
US8304408B2 (en) * 2007-05-24 2012-11-06 The Regents Of The University Of California Wnt signaling inhibitors, and methods for making and using them
EA030302B1 (ru) * 2008-11-21 2018-07-31 Форест Лэборетериз Холдингз Лимитед Антрахинондиоксимы и их применение
WO2011019648A1 (en) * 2009-08-10 2011-02-17 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
EP2470534A4 (en) * 2009-08-24 2013-02-27 Merck Sharp & Dohme INHIBITION OF JAK BLOCKES TOXICITIES ASSOCIATED WITH INTERFERENCE RNA
CA2775155A1 (en) * 2009-10-01 2011-04-07 Csl Limited Method of treatment of philadelphia chromosome positive leukemia

Also Published As

Publication number Publication date
IL232452A (en) 2017-01-31
EP2773607A4 (en) 2015-03-11
AU2012332111A1 (en) 2014-05-22
WO2013067547A1 (en) 2013-05-10
CN103917514A (zh) 2014-07-09
CA2853491A1 (en) 2013-05-10
IL232452A0 (en) 2014-06-30
MX2014005498A (es) 2016-05-05
ZA201403003B (en) 2017-08-30
ES2624427T3 (es) 2017-07-14
NZ624446A (en) 2016-01-29
JP6063472B2 (ja) 2017-01-18
EP2773607B1 (en) 2017-03-29
BR112014010584A2 (pt) 2017-05-02
CA2853491C (en) 2019-12-10
KR20140089418A (ko) 2014-07-14
US9238030B2 (en) 2016-01-19
KR102336767B1 (ko) 2021-12-10
EA027770B1 (ru) 2017-08-31
SG11201402056XA (en) 2014-10-30
CN103917514B (zh) 2016-11-16
AU2012332111B2 (en) 2016-11-17
JP2014534229A (ja) 2014-12-18
EA201490937A1 (ru) 2014-08-29
HK1198440A1 (en) 2015-04-24
EP2773607A1 (en) 2014-09-10
US20130143920A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
EA202190619A1 (ru) Противовирусные соединения
CO6480975A2 (es) Mimetico de smac
GEP20166438B (en) Imidazopyrrolidinone compounds
EA201591745A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh
EA201490420A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
BR112014013526A8 (pt) conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
MX343561B (es) Compuestos de imidazolpiridazina.
MX2014005498A (es) Metodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteina 1 similar a transducina b (tbl1), que inlcuyen la neoplasia mieloproliferativa y la leucemia mieloide cronica.
CU24265B1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, útiles en el tratamiento del cáncer
MA37866A1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
EA201491391A1 (ru) Терапевтически активные соединения и способы их применения
EA201290844A1 (ru) Соединения для ингибирования иммунопротеасом
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
EA201500574A1 (ru) Новые инданилоксидигидробензофуранилуксусные кислоты
EA201300388A1 (ru) Соединения замещенного бензамида
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
TN2014000112A1 (en) Ep1 receptor ligands
EA201590562A1 (ru) Бензамиды
EA201301114A1 (ru) Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний

Legal Events

Date Code Title Description
FG Grant or registration